Last updated 18 days ago

Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006)

784 patients around the world

Available in Chile, United States, Spain

Merck Sharp & Dohme LLC

784Patients around the world

This study is for people with

Lung cancer

Non-small cell lung carcinoma

Requirements for the patient

From 18 Years

All Gender

Medical requirements

StudyKEYVIBE-006

SponsorMerck Sharp & Dohme LLC

Study typeInterventional

Conditions

Non-small cell lung carcinoma

Requirements

From 18 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT05298423